Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
- DrugBank Accession Number
- DB10998
- Background
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.
There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Inactivated - Synonyms
- influenza A virus A/Brisbane/10/2010 (H1N1) antigen
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Influenza A virus A/Brisbane/10/2010 (H1N1) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated) hemagglutinin KFL1W6W9JB Not Available Not applicable - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Flucelvax Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/South Australia/55/2014 (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Utah/9/2014 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) Injection, suspension Intramuscular Novartis Vaccines And Diagnostics, Inc. 2014-07-01 2016-06-30 US 
Flucelvax Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) Injection, suspension Intramuscular Novartis Vaccines and Diagnostics GmbH 2013-08-30 2014-06-30 US Flucelvax Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Wisconsin/1/2010) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) Injection, suspension Intramuscular Novartis Vaccines and Diagnostics GmbH 2012-11-30 2012-11-19 US Flucelvax Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) Injection, suspension Intramuscular Novartis Vaccines And Diagnostics, Inc. 2014-07-01 2015-06-30 US Flucelvax Quadrivalent Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Hong Kong/259/2010 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Utah/9/2014 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) Injection, suspension Intramuscular Seqirus, Inc. 2016-07-01 2017-06-30 US Medical Provider Single Use EZ Flu Shot Flucelvax 2014-2015 Kit Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Isopropyl alcohol (70 mL/100mL) Kit Topical Asclemed Usa, Inc. 2013-07-01 2015-06-30 US Medical Provider Single Use EZ Flu Shot Flucelvax 2015-2016 Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/South Australia/55/2014 (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Influenza B virus B/Utah/9/2014 antigen (MDCK cell derived, propiolactone inactivated) (15 ug/0.5mL) + Isopropyl alcohol (70 mL/100mL) Kit Topical Asclemed Usa, Inc. 2014-07-01 2016-06-29 US
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- DES33X6VK7
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Basic Science Flu caused by Influenza 1 4 Completed Basic Science Flu caused by Influenza 1 4 Completed Other Asthma 1 4 Completed Prevention Flu caused by Influenza 1 4 Completed Prevention Immune Responses / Influenza, Human 2 4 Recruiting Basic Science Coronavirus Disease 2019 (COVID‑19) / Lymphoma 1 4 Recruiting Basic Science Flu caused by Influenza 1 3 Active Not Recruiting Prevention Influenza, Human 1 3 Completed Prevention Flu caused by Influenza / Humans / Viral Disease 1 3 Completed Prevention Influenza, Human 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, suspension Intramuscular Kit Topical - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:05 / Updated at June 12, 2020 16:53